Promising Efficacy and Safety With Four-Week Extended Dosing Data Shows Dose-Dependent Reduction of LDH and Increased Hemoglobin Levels That Demonstrate Clinically Meaningful Hemolysis Inhibition CANbridge Plans to
Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.
The combination of ibrutinib, obinutuzumab, and venetoclax was associated with prolonged survival in patients with newly diagnosed or relapsed/refractory mantle cell lymphoma.
Preliminary results from the PREACH-M trial show improvement in hematologic parameters in patients with RAS-mutant chronic myelomonocytic leukemia (CMML).